Smad4 is an intracellular transmitter of TGF-b signals and its tumor suppressor function is presumed to reside in its capacity to mediate TGF-b-induced growth inhibition. However, there is accumulating evidence that this hypothesis may be too simple. The roles of TGF-b in carcinogenesis are complex and also comprise tumor promoting functions particularly in late stage carcinogenesis. Importantly, functional inactivation of Smad4 in colon carcinomas frequently occurs at late stages when tumors acquire invasive and metastatic capabilities. We have previously reported that stable re-expression of Smad4 in SW480 human colon carcinoma cells was adequate to suppress tumor growth in nude mice. However, it did not affect cell growth in vitro nor did it restore TGFb responsiveness. Here, we report that Smad4 transcriptionally induced classical cadherins including the invasion suppressor E-cadherin, presumably re-establishing epithelial morphology. Smad4-induced cadherins were able to recruit catenins to the plasma membrane and were functionally active in cell -cell adhesion. These results indicate a novel pathway of Smad4-mediated tumor suppression and suggest that Smad4 in colon cells may be involved in the maintenance of epithelial traits.
Introduction
Smad4, first identified as DPC4 (deleted in pancreatic carcinoma, locus 4), is a tumor suppressor gene functionally inactivated in one half of pancreatic adenocarcinomas , in one third of metastatic colorectal cancers (Miyaki et al., 1999) , in every fourth carcinoma of the small intestine (Blaker et al., 2002) and in smaller subsets of other tumor types (Hahn et al., 1998; Schutte et al., 1996) . Smad4 belongs to the Smad gene family, which encodes intracellular signaling mediators of the TGF-b superfamily of cytokines. TGF-b cytokines signal through TGF-b type II and type I receptors, a family of transmembrane serine/threonine kinase receptors, which upon activation phosphorylate receptor interacting Smad proteins (R-Smads). Activated R-Smads form heteromeric complexes with Smad4, the common partner Smad (co-Smad), and translocate into the nucleus where they function as transcription factors.
As Smad4 is a key mediator of TGF-b responses, its cellular functions are commonly investigated as part of this signaling pathway. TGF-b cytokines have been shown to regulate a wide range of cellular responses such as proliferation and differentiation, migration and apoptosis during embryogenesis and in the maintenance of tissue homeostasis in the adult (Kingsley, 1994; Massague, 1998; Roberts and Sporn, 1990) . In tumor biology most attention has been paid to TGFb's role as a prototype negative growth factor potently inhibiting the growth of normal epithelial cells. Tumor cells typically acquire TGF-b resistance, allowing them to escape normal growth constraints. Mutational inactivation of the TGF-b type II receptor has been identified as the underlying mechanism for TGF-b resistance in microsatellite unstable colon cancers (Markowitz et al., 1995) . When Smad4 was identified as a tumor suppressor, its functional inactivation was considered an alternative mechanism to cause TGF-b resistance and Smad4's ability to transmit TGF-b induced growth inhibitory signals was supposed to underlie its tumor suppressor function. Experimental proof for this hypothesis, however, is still missing: suppression of tumorigenicity in vivo through restoration of TGF-b growth inhibition by Smad4 reexpression has not yet been shown. Moreover, there is accumulating evidence that the acquisition of TGF-b resistance and loss of Smad4 may be independent events. For example, certain TGF-b transcriptional responses are retained in Smad4 deficient cells (Hocevar et al., 1999; Sirard et al., 2000) and several Smad4 deficient tumor cell lines are still growth inhibited by TGF-b (Dai et al., 1999; Fink et al., 2001) .
The relationship of TGF-b and Smad4 is further complicated by the fact that TGF-b has a dual and paradoxical role in carcinogenesis (Akhurst and Balmain, 1999; Derynck et al., 2001; Gold, 1999; Massague et al., 2000; Piek and Roberts, 2001 ; Reiss, 1997 Reiss, , 1999 . While acting as a tumor suppressor in early stages of cancer development through growthinhibitory and pro-apoptotic activities, TGF-b is often overexpressed in late stage carcinogenesis, suggesting that it promotes tumorigenesis. TGF-b's tumor promoting function may reside in part in its paracrine effects. For example, TGF-b exerts local and systemic immune suppression and can induce angiogenesis. In addition, TGF-b has been implicated in the epithelial to mesenchymal transition of tumor cells (Bhowmick et al., 2001; Cui et al., 1996; Ellenrieder et al., 2001; Kitagawa et al., 1996; Miettinen et al., 1994; Oft et al., 1998; Piek et al., 1999; Portella et al., 1998; Zavadil et al., 2001) , which characterizes invasive and metastatic carcinomas. The roles of the Smad proteins in these processes remain to be elucidated.
Mediating TGF-b responses is only one of the many putative functions of Smad4 as a signaling molecule. Smad4 is the only co-Smad in mammalian cells and is thus potentially involved in signal transmission of all members of the TGF-b superfamily, many of which are multifunctional regulators in development and growth control. Smad signaling is also interconnected with other signaling cascades through a variety of cross-talk mechanisms (for review see Attisano and Wrana, 2000; Massague et al., 2000; ten Dijke et al., 2000; Zhang and Derynck, 1999) . Moreover, Smads functionally cooperate with a number of transcription factors, transcriptional coactivators and repressors, and these are in turn targets for regulation through other signaling pathways. The loss of Smad4 in an incipient tumor cell, consequently, may not only affect one linear signaling pathway, but may induce complex alterations in the signaling networks. Thus, deciphering the functions of Smad4 as a tumor suppressor requires models that are able to reflect the complexity of this molecular and cellular context. For this we have recently established stable Smad4 transfectants derived from Smad4-deficient human carcinoma cells. Re-expression of Smad4 in SW480 colon and Hs766T pancreatic carcinoma cells was sufficient to suppress tumor formation in nude mice providing definite proof for its functional activity (Schwarte-Waldhoff et al., 1999 . Yet, Smad4 re-expression did not exert growth inhibitory effects nor did it restore sensitivity to TGF-b in vitro indicating that the acquisition of TGF-b resistance and loss of Smad4 may be independent events (Schwarte-Waldhoff et al., 1999 . Retained TGF-b resistance in Smad4-positive cells may be due to limited expression levels of the TGF-b type II receptor.
To dissect mechanisms of Smad4 mediated tumor suppression we have analysed constitutive differences between Smad4 re-expressing and Smad4-negative SW480 cell clones. The previous observation, that Smad4 re-expression induced a transition from a spindle cell shape to an epithelioid morphology with close intercellular contacts, prompted us to investigate the expression of cadherins, key molecules in the establishment and maintenance of cell -cell adhesion and of epithelial differentiation (Bracke et al., 1996; Gumbiner, 1996) . This study shows that stable reexpression of Smad4 in SW480 cells transcriptionally induces classical cadherins, influences subcellular distribution of catenins and thus restores epithelial type intercellular adhesion. These findings indicate a novel TGF-b independent way of Smad4 mediated tumor suppression and suggest that the tumor suppressor Smad4 may be involved in transcriptional regulation of the tumor suppressor E-cadherin and the highly related P-cadherin.
Results
Re-expression of Smad4 at physiological levels is not adequate to restore TGF-b responses in SW480 cells SW480 human colon carcinoma cells are Smad4-deficient. They have lost one copy of chromosome 18, where the Smad4 gene is located; the second Smad4 allele harbors a splice site mutation and is not expressed (Woodford-Richens et al., 2001) . Through stable restoration of Smad4 in these cells we have previously provided definite proof for Smad4's functional activity as a tumor suppressor. Re-expression of Smad4 at roughly physiological levels was adequate to suppress tumor growth in vivo in nude mice (SchwarteWaldhoff et al., 1999) . Surprisingly, however, reexpression of Smad4 did not affect cell growth in vitro and was not sufficient to restore TGF-b antiproliferative responses (Schwarte-Waldhoff et al., 1999) .
To further elucidate the relationship of TGF-b and Smad4 we analysed TGF-b target genes in SW480 transfectant clones. Interestingly, basal expression levels of the cyclin dependent kinase inhibitor p21(Cip-1/ WAF-1), a prototype antiproliferative TGF-b response gene, were consistently increased in all Smad4-positive SW480 cell clones, whereas levels of plasminogenactivator-inhibitor 1 (PAI-1), another 'classical' TGF-b response gene, were reduced (Figure 1a) . However, neither in Smad4-negative control clones nor in Smad4 re-expressing tumor suppressed revertants could we observe any significant alterations of either p21(Cip-1/ WAF-1) (Figure 1b) or PAI-1 RNA levels (data not shown) in response to incubation with high concentrations of recombinant active TGF-b. In contrast, two well-known TGF-b responsive control cell lines, HaCaT and MDA-MB-231, yielded the expected results: p21(Cip-1/WAF-1) and PAI-1 RNA levels were rapidly and strongly induced by incubation with TGF-b1 (Figure 1c) , confirming that performance of the assay was adequate. We have previously provided evidence that low expression levels of TGF-b receptors may limit TGFb responses in SW480 cells (Schwarte-Waldhoff et al., 1999) . Smad4 re-expressing SW480 cells displayed moderate responses in transient transfections with p3TP-Lux, the most commonly used reporter to measure TGF-b responsiveness. When a plasmid encoding a constitutively active TGF-b receptor was cotransfected the responses were significantly increased. Smad4 negative SW480 cells still did not respond to p3TP-Lux transfection, whether the receptor was coexpressed or not. Here, we investigated endogenous expression levels of the classical TGF-b receptors through sensitive ribonuclease protection analysis. Expression levels of the TGF-b type I receptor were high, however, RNAs encoding the type II receptor were virtually undetectable in SW480 cells (Figure 1d ). Thus, retained TGF-b resistance in Smad4-re-expressing SW480 clones may be due to low expression levels of TGF-b RII.
Re-expression of Smad4 induces the expression of E-cadherin and P-cadherin in SW480 cells
We have shown that restoration of TGF-b responses is dispensable for Smad4-mediated tumor suppression. To address TGF-b independent mechanisms that underlie Smad4-mediated tumor suppression in stable SW480 revertants, we further investigated constitutive differences between Smad4-negative and Smad4-reexpressing SW480 cells. We have previously reported that Smad4 restoration induced significant alterations in cellular morphology in vitro (Schwarte-Waldhoff et al., 1999) . SW480 parental cells as well as Smad4-negative vector transfectants displayed a spindle shape or rounded morphology and a criss-cross growth pattern at confluency (Figure 2a ). In contrast, Smad4 revertant clones consistently showed a conversion into an epithelioid morphology: cells were well-attached, grew in clusters of interconnected cells at low densities and formed epithelial-like layers when reaching confluency ( Figure 2a ). As intercellular contacts in epithelial cells are primarily mediated by E-cadherin, this observation prompted us to analyse expression of E-cadherin. In dense cultures of Smad4-negative SW480 control clones, virtually no E-cadherin reactivity was detected by indirect immunofluorescence (Figure 2b ). In contrast, Smad4-positive SW480 cells displayed a honeycomb-like pattern of E-cadherin expression at sites of cell -cell contacts which is typical for epithelial cell layers.
E-cadherin protein levels were consistently increased in all independent Smad4-positive SW480 clones analysed indicating that E-cadherin induction was a (Figure 3a) . Northern blotting revealed strongly increased steady-state RNA levels E-cadherin in Smad4-positive SW480 cells, suggesting that Smad4 operates at the level of transcription (Figure 3b ). This was confirmed in promoter analyses using transient transfection analyses with an E-cadherin promoter luciferase construct. Ecadherin promoter activity proved to be significantly increased in Smad4-positive SW480 cells, suggesting that E-cadherin induction is due to increased transcription (Figure 3c ).
Expression analysis of other classical cadherins revealed that P-cadherin was also strongly induced through Smad4 re-expression (Figure 4) . N-cadherinspecific transcripts were not detected, either in Smad4-negative or in Smad4-positive clones (data not shown).
Smad4-upregulated cadherins are functional
Cadherins are transmembrane proteins whose extracellular domains interact in a zipper-like fashion to connect adjacent cells. Critical for cell -cell adhesion is the interaction of the intracellular cadherin domain with the catenins, a group of proteins which link cadherins to the actin cytoskeleton. Thus, we analysed catenin expression and localization through indirect immunofluorescence. Smad4-negative SW480 cells showed strong staining for a-and b-catenin in the cytoplasm and the nucleus (Figure 5a ). Smad4 reexpressing cells, in contrast, appeared depleted of cytoplasmic and nuclear catenins and showed strong a-and b-catenin staining at the plasma membrane colocalizing with E-cadherin (Figure 5a ). To assess the subcellular distribution of catenins in a more quantitative way, membrane and soluble cell fractions were separated by concanavalin-A precipitation and analysed by Western blotting (Figure 5b ). E-cadherin was used as a control for membrane association. This analysis confirmed that a-and b-catenins were recruited to the plasma membrane in Smad4-positive cells, presumably through interaction with the cadherins. Most of the cellular catenins, however, remained in the soluble fraction (note that different portions of membrane and soluble fractions are loaded on the gel). 
Smad4 induces E-cadherin in vivo
We have previously reported, that re-expression of Smad4 in SW480 cells was adequate to suppress tumor growth after subcutaneous injection in nude mice. Smad4 negative SW480 cells produced progressively growing tumors which reached a size of 1 cm in diameter after 5 -8 weeks. No tumors derived from Smad4 re-expressing cells could be detected after the same period. Interestingly, we repeatedly detected very small tumors (1 -4 mm in diameter) roughly 2 weeks after injection of both Smad4 negative or Smad4 positive SW480 cells. Tumors derived from Smad4 positive cells completely disappeared 3 -4 weeks after injection. As this behavior was highly reproducible, we sacrificed mice 2 weeks after injection of the cells to study these 'transient' tumors compared to tumors derived from Smad4 negative cells.
Smad4 negative SW480 cells formed poorly differentiated tumors with a predominantly solid growth pattern (Figure 7a ). On the other hand, tumors derived from Smad4 positive cells displayed an increased proportion of stromal constituents and showed a tendency towards tubular differentiation (Figure 7a ). Both exhibited abundant surrounding fibrous tissue containing mesenchymal as well as inflammatory cells. Expression of Smad4 and E-cadherin in vivo was analysed by immunohistochemistry. Smad4 re-expressing SW480 tumor cells displayed moderate expression levels of nuclear and cytoplasmic Smad4 (Figure 7b ). Murine stromal and inflammatory cells were also Smad4 reactive, since the antibody also detects the murine Smad4 protein. In tumors derived from Smad4 negative SW480 cells scattered Smad4 positive cells of murine origin were also detected, but the carcinoma cells did not show any immunoreactivity (Figure 7b ). Importantly, immunohistochemical staining for Ecadherin expression showed strong differences in Ecadherin expression levels in vivo: E-cadherin staining was barely seen in Smad4 negative tumor cells ( Figure  7c ). In contrast, membrane-associated E-cadherin was readily detected in Smad4 positive carcinoma cells, confirming that Smad4-dependent induction of Ecadherin expression was functional in vivo (Figure 7c ).
Discussion
Through stable re-expression of Smad4 we have investigated the cellular and molecular mechanisms that underlie Smad4 function as a tumor suppressor. Here we show that re-expression of Smad4 in SW480 human colon carcinoma cells, adequate to mediate tumor suppression in vivo, is associated with the induction of functionally competent cadherins, with restoration of cell -cell adhesion and with morpholo- Tumor suppressor Smad4 induces cadherins N Müller et al gical reversion to an epithelioid phenotype. These findings indicate a novel mechanism for Smad4-mediated tumor suppression and suggest that loss of Smad4 in colon carcinogenesis may be associated with loss of epithelial traits and with the acquisition of invasive and metastatic capabilities of incipient tumor cells.
We have previously shown that stable re-expression of Smad4 is adequate to suppress tumor growth in nude mice whereas it does not affect cell proliferation in vitro (Schwarte-Waldhoff et al., 1999 . To rule out potential artefacts due to Smad4 overexpression we carefully compared Smad4 protein levels in SW480 cell clones to endogenous Smad4 levels of various normal and transformed cell lines (Schwarte-Waldhoff et al., 1999 and data not shown). Smad4 levels in reconstituted SW480 cells were among the lowest detected. Moreover, in nude mouse tumors derived from Smad4 re-expressing SW480 cells, Smad4 protein expression was similar in human epithelial cells and mouse stroma, whereas in the normal mouse gut as in humans epithelial cells stain more intensely as compared to the stromal constituents (data not shown). Our findings are also not due to a selection bias, as all Smad4 dependent changes are consistently found in each independent SW480 clone analysed. Initial transfection efficiencies using the Smad4 expression vector and the empty vector control were very similar, thus excluding a general selection bias.
The failure to restore TGF-b responsiveness through stable re-expression of Smad4 suggests that TGF-b resistance of SW480 cells is not due to Smad4 deficiency. SW480 human colon carcinoma cells have accumulated a number of genetic alterations characteristic for colon carcinomas, among them the mutational inactivation of the tumor suppressor gene APC, an activating mutation of the Ki-ras oncogene and a mutated p53 gene, all of which had previously been were also Smad4 reactive. (c) E-cadherin was virtually absent from Smad4 negative tumors, but showed a strong membraneous expression on Smad4 re-expressing carcinoma cells in vivo. Magnification: 1006 and 2006 (inserts) implicated in the control of TGF-b responsiveness. We have here provided evidence that expression levels of the TGF-b type II receptor may be limiting TGF-b responsiveness. Interestingly, inactivation of both the Smad4 gene and a TGF-b receptor gene have been reported to occur together both in pancreatic and in colorectal tumors (Kern, 1998) . Also, nuclear localization of Smad4, indicating transcriptional activity, has been reported in human carcinomas which lack a functional TGF-b receptor (Montgomery et al., 2001) , suggesting that TGF-b responsiveness is not necessary for Smad4 functions as transcriptional regulator. Smad4 was also localized nuclear in transient nude mouse tumors derived from Smad4 reconstituted SW480 cells studied here, indicating that the Smad4 protein is functionally active in these cells in the in vivo environment.
Focusing on Smad4 dependent changes in the absence of exogenous administration of ligand, we show here that Smad4 upregulates E-cadherin and Pcadherin. The role of E-cadherin in cancer development and progression has been extensively investigated and its status as a suppressor of invasion and metastasis is firmly established based on a number of immunohistochemical, functional and genetic approaches (Behrens, 1999; Christofori and Semb, 1999; Guilford, 1999; Nollet et al., 1999; Wijnhoven et al., 2000) . In human cancers, E-cadherin can be inactivated through genetic mechanisms including germline mutations in inherited diffuse-type gastric cancers and somatic mutations in lobular breast cancers (Berx et al., 1998) . In addition, functional inactivation due to promoter hypermethylation has been described. In many cancer types, however, mechanisms for Ecadherin downregulation remain elusive. Here we provide evidence for a role of the tumor suppressor Smad4 in positively regulating E-cadherin suggesting that functional inactivation of Smad4 during carcinogenesis may represent a novel mechanism for Ecadherin reduction in invasive tumors.
How Smad4 mediates increased expression of Ecadherin and P-cadherin at the molecular level is not fully understood. We propose that Smad4 acts at the level of transcription because the activity of an Ecadherin promoter construct was increased in Smad4 re-expressing cells. Smad4 may thus act on the cadherin promoter directly or indirectly either by competition for transcriptional coregulators or by induction or reduction of other transcription factors regulating cadherins. E-cadherin transcriptional regulation is complex and presumably involves the combined activities of positive and negative regulators binding to different regulatory sequence elements in the proximal promoter region and in intron 1 (Bussemakers et al., 1994; Giroldi et al., 1997; Hennig et al., 1995 Hennig et al., , 1996 . The E-boxes have been investigated in detail and have previously been implicated in silencing E-cadherin expression in tumor cell lines and in fibroblasts (Hennig et al., 1995) . A number of transcription factors have been identified that may function in repression of E-cadherin, among them Snail (Batlle et al., 2000; Cano et al., 2000) , SIP-1 (Smad interacting protein-1) (Comijn et al., 2001; and SLUG (Hajra et al., 2002; Savagner et al., 1997) , all of which bind to the E-box elements. Smad4 might directly or indirectly impinge on (one of) these factors and thus relieve E-cadherin from repression.
Smad4-induced cadherins proved to be functionally competent in recruiting catenins to the plasma membrane and in mediating cell -cell adhesion in aggregation assays. As loss of intercellular adhesion is a prerequisite for invasive tumor growth, these findings suggest an association of Smad4 loss with the acquisition of invasiveness. This conclusion is also consistent with recent results from detailed genetic and immunohistochemical analyses of colorectal and pancreatic carcinomas which have assigned Smad4 loss to invasive and particularly metastatic stages (Luettges et al., 2001; Maitra et al., 2000; Miyaki et al., 1999; Wilentz et al., 2000) . In addition, a mouse knock-out model also suggests an association of Smad4 loss with the acquisition of invasiveness. Whereas APC single knock-out mice, a model for human familial adenomatous polyposis (FAP), develop numerous benign polyps in the small intestine and colon (Oshima et al., 1995) , tumors in APC/DPC4 compound double knockout mice frequently progressed into malignant lesions invading into the submucosa (Takaku et al., 1998) .
Stable re-expression of Smad4 in SW480 cells, in addition to increasing the levels of E-cadherin and Pcadherin, induced a complex reprogramming of gene expression profiles (Schwarte-Waldhoff, unpublished data) and phenotypic properties. Cells are reverted to an epithelioid phenotype, showing features of polarization (Reinacher-Schick et al., manuscript in preparation). Thus, Smad4-re-expression may impinge on a number of cellular properties and several of these may contribute to Smad4's tumor suppressor function(s). As E-cadherin is a bona fide tumor suppressor we propose that induction of cadherin expression plays a significant role in Smad4-mediated tumor suppression. E-cadherin is supposed to exert tumor suppressor activity through its role as a prime mediator of adherens junctions in epithelia. Intercellular contacts prevent cells from detaching from the epithelial cell layer, an essential step in the acquisition of invasiveness. Moreover, cell adhesion is intimately linked to signaling cascades that regulate cell proliferation and survival in vitro and in vivo. E-cadherin tumor suppressor activity could also result from its impact on b-catenin signaling activity through recruitment of b-catenin to the plasma membrane and depletion of the signaling competent cellular b-catenin pool. SW480 cells, however, are known to express very high levels of b-catenin presumably due to inactivation of the APC tumor suppressor. In Smad4-positive SW480 cells we did show recruitment of a-and b-catenins to the plasma membrane but only a small portion of the total cellular catenins was affected. In line with this, Smad4 re-expression was not associated with decreased bcatenin/TCF signaling as determined by a reporter assay (data not shown).
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In summary, our results indicate that Smad4's tumor suppressor functions are not necessarily confined to its role as a component of the linear TGF-b signaling pathway. We here provide evidence that Smad4 may be involved in transcription regulation of the tumor and invasion suppressor E-cadherin and P-cadherin. Importantly, Smad4-mediated induction of E-cadherin is retained in vivo in nude mouse tumors. Though the mechanisms underlying suppression of tumor growth in Smad4 positive SW480 cells are not fully understood, the association of Smad4, a tumor suppressor functionally inactivated upon the acquisition of invasiveness, with regulation of the invasion suppressor E-cadherin is compelling and may stimulate further research to investigate the scope of these results.
Materials and methods

Cell cultures
SW480 and MDA-MB-231 cells were obtained from the American Type Culture Collection (Rockville, MD, USA), HaCaT cells (Boukamp et al., 1988) were the kind gift of Drs P Boukamp and N Fusenig. Cells were maintained in DMEM supplemented with antibiotics and 10% fetal calf serum (GIBCO). The full-length coding sequence of Smad4/DPC4 was cloned into the pBK-CMV expression vector (Stratagene) and Smad4 re-expressing SW480 cell clones and negative control transfectants were established by a standard calcium phosphate coprecipitation method as described (SchwarteWaldhoff et al., 1999) . Transfectants were maintained in medium with geneticin (0.2 mg/ml; GIBCO). To analyse TGF-b responses serum-deprived cells were incubated with recombinant TGF-b1 (5 ng/ml; R&D Systems) and RNA was harvested at the indicated time points.
Northern blot analysis and ribonuclease protection assay RNA was isolated by acid phenol extraction or using a commercial kit (RNeasy; Quiagen). Northern blots and hybridizations were performed as described (SchwarteWaldhoff et al., 1999) . For loading control blots were stripped and reprobed for GAPDH. Ribonuclease protection assays were performed with the 'human cytokine receptor set hCR-4' (Pharmingen) according to the manufacturer's protocol. Signals were quantified by PhosphorImager analysis (Packard).
Preparation of proteins, glycoprotein fractionation and Western blot analysis
Cells were lysed in NP-40 lysis buffer (25 mM Tris HCl, pH 7.4, 0.5% NP-40, 100 mM NaCl, 1 mM EDTA) containing a protease inhibitor cocktail (Roche) and 1 mM PMSF. Purification of glycoprotein bound and unbound fractions of a-and b-catenin or E-cadherin was performed as described (Fagotto et al., 1996) . In brief, 300 mg of total protein were incubated overnight at 48C with 50 ml (*300 mg concanavalin) concanavalin A (conA)-Sepharose (Sigma Aldrich). Total protein lysates or ConA-fractionated proteins were subjected to standard SDS -PAGE and immunoblot analysis which was performed as described (Schwarte-Waldhoff et al., 1999) . In case of a-catenin or b-catenin detection a threefold or sixfold larger proportion of the conA-bound fraction compared to unbound fraction, respectively, were loaded on the gel. The blots were incubated with monoclonal antibodies against Smad4 (anti-Smad4 B8; dilution 1 : 500, Santa Cruz), E-cadherin (HECD-1, dilution 1: 1000, Zymed) and Pcadherin (NCC-CAD-299, dilution 1 : 500, Zymed) or with polyclonal rabbit antiserum (anti-b-catenin or anti-a-catenin, diluted 1 : 5000 and 1 : 2000, respectively). As loading control for Western analysis, blots were co-stained for b-tubulin (TUV 2.1, dilution 1 : 1000, Sigma).
Confocal immunofluorescence microscopy
Cells were grown to confluency on glass coverslips, rinsed with PBS and fixed with ice-cold 100% methanol for 5 min at 7208C. The fixed cells were incubated with primary antibodies HECD-1 (anti human E-cadherin, Zymed, dilution 1 : 100 in PBS+1% BSA) and rabbit antisera (anti human bcatenin or anti human aE-catenin; dilution 1 : 200 in PBS+1% BSA) for 1 h followed by FITC or Cy3-conjugated secondary antibodies (FITC-coupled anti-mouse Ig, dilution 1 : 200, Dianova; Cy3-coupled anti-rabbit Ig, dilution 1 : 1000, Dianova). Samples were mounted with Vectashield (Vector Laboratories, Burlinghame, CA, USA) and examined with a Zeiss LSM 410 confocal laser-scanning immunofluorescence microscope (Carl Zeiss, Jena, Germany).
Aggregation assay
Cells were grown to 70 -80% confluency on 10-cm cell culture dishes, washed and detached by incubation in PBS without Ca 2+ and Mg 2+ for 15 -20 min. Cells were centrifuged for 5 min at 800 r.p.m. and resuspended as single cell suspensions by repeated pipetting. Cells at a concentration of 5610 5 cells/ml in standard growth medium were plated on bacterial plates and incubated at 378C on a horizontal shaker at 100 r.p.m. for 1 h. Then, photographs of randomly chosen areas were taken with a digital camera. The number of single cells, cell aggregates (as defined by more than five cells per cluster) and the mean area of aggregates were determined using ImagePro software. For determination of calcium dependency of aggregate formation, cells were incubated in HBSS medium containing 2% FCS plus either 2 mM EGTA (pH 8.0) or 2 mM CaCl 2 .
E-cadherin reporter gene assay SW480 cells (3610 5 cells per 10 cm 2 well) with either no or reconstituted SMAD4 expression were cotransfected with 500 ng human E-cadherin reporter plasmid (Comijn et al., 2001) and 500 ng internal standard, i.e. b-galactosidase expression plasmid pUT651 (Eurogentec). Three days after transfection, cells were harvested and cell extracts were assayed for luciferase and b-galactosidase activity with the Galacto-Star kit (Tropix). E-cadherin promoter activity was normalized versus b-galactosidase activity.
Immunohistochemistry
Tumorigenicity assays in nude mice were performed as described (Schwarte-Waldhoff et al., 1999) . Subcutaneous tumor tissues were fixed in neutral-buffered formaldehyde (4%) and embedded in paraffin according to routine procedures. Serial sections (4 mm thick) were stained with H&E and immunostained with mabs directed against Smad4 (clone B8, dilution 1 : 100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and E-cadherin (clone 5H9, dilution 1 : 40; Progen Biotechnik, Heidelberg, Germany). Antigen retrieval was achieved by microwave treatment (665 min for Smad4; 465 min for E-cadherin) and staining was performed as described earlier (Baldus et al., 1998) . Briefly, after blocking of endogenous peroxidase by 1% H 2 O 2 /methanol, normal swine serum (X0901, dilution 1 : 20; Dako, Hamburg, Germany) was added for 30 min at 378C. Primary mABs were incubated overnight at 48C, followed by biotinylated rabbit-anti-mouse immunoglobulin (E354, dilution 1 : 400; Dako) for 30 min at room temperature (RT) and streptavidin-peroxidase conjugate (P397; dilution 1:400, Dako) for 30 min, RT. The reaction was visualized by 200 mg/ml 3-amino-9-ethyl-carbazol (Sigma, Munich, Germany) in 50 mM sodium acetate buffer containing 5% dimethylformamide and 0.1% H 2 O 2 for 30 min, RT. Slides were counterstained with hematoxylin and mounted in glycerol jelly. 
